Latest News

Although skeletal-related events (SREs) are linked with a reduced quality of life and worse outcomes, to the authors’ knowledge the factors that predict SREs are minimally understood. The objective of the current study was to identify predictors of SREs and all-cause mortality among men with metastatic castration-resistant prostate cancer (mCRPC). Data were collected on 837 […]

GU-114: Overcoming Checkpoint Inhibitor Resistance With Epigenetic Therapy in Urothelial Cancer Condition: Urothelial Carcinoma Intervention: Drug: Atezolizumab Drug: Guadecitabine Purpose: This is a single arm Phase II study with a safety run-in to identify the recommended phase II dose of the combination therapy of atezolizumab and guadecitabine. Patients with recurrent/advanced urothelial carcinoma (stage IV) who […]

A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer (BL-AIR: Bladder Cancer-Avelumab for Invasive Resectable Disease) Condition: Bladder Cancer, Metastatic Bladder Cancer, Invasive Bladder Cancer Intervention: Drug: Avelumab Purpose: This is a pilot study of avelumab in patients with non-metastatic, muscle invasive bladder cancer who are eligible for radical cystectomy (RC), but […]

Intravesical Mistletoe Extract in Superficial Bladder Cancer: A Phase III Efficacy Study Condition: Superficial Bladder Cancer Intervention: Drug: abnobaVISCUM 900 Drug: Mitomycin C Purpose: The aim of this phase III study is to assess the efficacy of abnobaVISCUM® 900 compared with Mitomycin C (MMC) monotherapy in patients with superficial bladder carcinoma by evaluation of the […]

Active Surveillance of the Small Renal Mass: An Integrated Biomarker Trial Condition: Small Renal Mass, Kidney Cancer Purpose: Active surveillance in kidney cancer involves closely observing the tumor with periodic imaging studies rather than immediately proceeding to an invasive treatment. This does not mean that the tumor is ignored or that future treatment is not […]

A Pilot Study of Preoperative Nivolumab in High-Risk Non-Metastatic and Metastatic Renal Cell Carcinoma Condition: Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7 Intervention: […]

Biomarker Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer Condition: Metastatic Prostate Cancer Intervention: Other: Saliva, Blood, or Existing Tissue Sample Collection and Analysis Purpose: The purpose of this study is to evaluate the prevalence of 4 or more DNA-repair defects in a population of men with metastatic Prostate Cancer […]

Pilot Study: Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer Condition: Prostate Neoplasm Intervention: Drug: Lu-177 PSMA-617 Purpose: Radioligand therapy (RLT) using Lu-177 labelled PSMA is a promising new therapeutic approach to treat metastatic prostate cancer. This tumor-specific treatment is directed against prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer cells. In the last […]

San Francisco, CA (UroToday.com) — Astellas Pharma Inc., President and CEO: Kenji Yasukawa, Ph.D., announced that the U.S. Food and Drug Administration (FDA) has accepted for review the filing of a supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) to add an indication for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC). The application has […]